Tobacco and Nicotine Products Regulation and Policy Conference
October, 2026 | In-Person & Virtual Event
Overview
Join a uniquely diverse and influential group of stakeholders—public health leaders, researchers, manufacturers, attorneys, consumer advocates, entrepreneurs, and federal and state regulators—for the premier annual conference on regulating the full spectrum of tobacco and nicotine products in the United States.
As the only neutral convenor that brings all perspectives to the same table, this two-day event creates a rare forum for candid, balanced dialogue across sectors. Attendees will hear directly from the FDA on the latest regulatory developments, guidance documents, and policy initiatives shaping the marketplace.
The program features timely, in-depth discussions on the most pressing tobacco and nicotine issues, along with interactive panels designed to foster meaningful exchange between speakers and participants—ensuring voices from every corner of the field are heard.
Register – Registration Open Soon
Call for Submissions
FDLI invites you to submit a proposal for a session for the Tobacco and Nicotine Product Regulation and Policy Conference. Your submissions and input are integral to ensuring that the most timely and pertinent topics are covered at the conference. Topics should address issues relating to marketing, labeling, compliance, enforcement, and litigation as it impacts tobacco and nicotine products regulation and policy in the United States.
The Call for Proposals will be open through March 16, 2026.
Proposal Submission Guidelines
- Proposed topics should be at an advanced level.
- Provide important details and context: why the topic is important, who is affected, and relevant regulatory, legislation, guidance, or newsworthy developments.
- As a neutral convener, FDLI prefers topics that include multiple perspectives, including government, industry, private attorneys, academics, and public interest.
- FDLI prefers submissions to include a reasonably detailed and thoughtful title for and description of the proposed session.
Submissions FAQ
- Q: Am I limited in the number of proposals I can submit?
- A: Multiple submissions from the same person or organization are welcome; however, each proposal requires its own form.
- Q: How will my submission be reviewed?
- A: All submissions are blinded before being reviewed by the Tobacco and Nicotine Programs Committee. All submissions are treated as recommendations, and proposals may be modified or combined by FDLI to best suit the needs of the conference.
- Q: Do all items in my proposal need to be in final form?
- A: No—Your proposal does not need to be in final form. A proposal can and will likely be updated by the Committee to include the newest or most up-to-date information as relevant for the FDLI audience.
- Q: Should I reach out to speakers I suggest in advance of submitting my proposal?
- A: Suggested speakers should not be invited in advance—sessions are often combined and we cannot guarantee that suggested speakers will be included.
- Q: Can I email you my submission?
- A: All submissions must be received through the submission portal.
- Q: If my topic is selected, do I get to speak? Do I have to speak if my topic is selected?
- A: Speaking opportunities are generally reserved for FDLI members. If your topic is selected, you will be invited to speak if you are interested; however, speaking is not a requirement to submit a topic.
- Q: How will I know if my submission is accepted?
- A: You will be notified of the status of your submission approximately three months before the conference date.
Proposal Submission Timeline
- March 16, 2026: Call for Proposals closes.
- June 2026: Those who submitted proposals will be notified of their submission’s status.
Sponsors
Gold
Sponsorship opportunities are available. Contact Cathy Scolieri for more information. View 2026 Sponsorship Opportunities
Planning Committee
Tony Abboud, Vapor Technology Association
Jasjit S. Ahluwalia, Brown University
Maham Akbar, Truth Initiative
Shelly Blackwell, EAS Consulting Group
Melis Coraggio, King & Spalding LLP
Kenneth Michael Cummings, Medical University of South Carolina
Jonathan Foulds, Penn State University
Joe G. Gitchell, Pinney Associates, Inc.
Bryan M. Haynes, Troutman Pepper Locke
Eshael M. Johnson, FDA-CTP
Eric Lindblom, O’Neill Institute for National and Global Health Law, Georgetown Law
John L Marshall, Altria Client Services LLC
Elliott McDowell, Philip Morris International
Willie Mckinney, McKinney Specialty Labs LLC
Robin J. Mermelstein, University of Illinois-Chicago
Brian J Miller, Johns Hopkins University
Jason Robinson, JUUL Labs
Barry Schaevitz, Fox Rothschild LLP
Valerie Briggs Solomon, R.J. Reynolds Tobacco Company
Andrew Tardiff, Campaign for Tobacco-Free Kids
Mark J. Vaders, Womble Bond Dickinson (US) LLP
LieAnn T. Van-Tull, Keller and Heckman LLP
Jeffrey Weiss, DF Medical Ventures
Jessica Zdinak, Applied Research and Analysis Company LLC



